NCT02209987 - Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Ulcerative Colitis

Interventions

DRUG

GS-5745 SC

GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe

DRUG

GS-5745 IV

GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials

Trial Locations (1)

Christchurch